Australia Hypodermic Syringes and Needles Market Size, Share, Growth and Forecast, 2025-2035

Chronic care, vaccines and safety rules sustain demand

The Australia hypodermic syringes and needles market was valued at USD 124.5 million in 2025 and is projected to increase from USD 137.0 million in 2026 to USD 215.6 million by 2035, registering a CAGR of 5.17% during 2026–2035. Demand comes from hospitals, clinics, pharmacies, aged care homes and public health programs that give injections, draw blood, prepare medicines and supply clean equipment to people who inject drugs. New South Wales and ACT held the largest regional share, 36.3% in 2025, because the zone has the largest population and hospital network. Western and Central Australia is the fastest-growing region at 5.61% a year, as population and vaccination numbers in Western Australia rise quickly. In turn, NSW Health introduced a new guideline on occupational exposure in March 2024 that supports the use of safety-engineered sharps devices.

Which injection devices does the estimate cover?

The estimate measures the value of single-use general-purpose syringes, insulin syringes and standalone hypodermic and pen needles sold in Australia, in conventional, shielded safety and retractable safety designs. It counts purchases by public-sector buyers, private healthcare providers and individual purchasers through public contracts, private provider contracts, pharmacies and online medical stores.

The estimate excludes prefilled syringes sold with a drug, insulin pens and pumps, intravenous catheters and needle-free injectors. The value chain runs from overseas manufacturers through Australian subsidiaries, medical distributors and state purchasing agencies to hospitals, pharmacies, aged care homes and patients.

General syringes lead while needles and safety devices rise

Why do general-purpose syringes lead value?

Based on product type, the market is categorized into general-purpose syringes, insulin syringes and standalone needles. General-Purpose Syringes led with a 52.0% share of 2025 value, because hospitals and clinics use them for injections, blood draws and medicine preparation. Standalone Needles grow fastest at 5.78% a year, as safety needles and pen needles gain use in hospitals, pharmacies and homes.

How do hospitals and home care split device use?

Based on care setting, the market is categorized into hospitals and clinics, ambulatory care and pharmacies, home and aged care, and public health and clinical research. Hospitals and Clinics led with a 48.0% share of 2025 value, because they give the most injections and infusions. Home and Aged Care grows fastest at 5.93% a year, as an older population receives more care at home and in aged care homes.

Why does therapeutic injection lead applications?

Based on application, the market is categorized into therapeutic injection, immunization, harm reduction and medication preparation and clinical testing. Therapeutic Injection led with a 42.0% share of 2025 value, because insulin, antibiotics and other injected medicines need daily doses. Therapeutic Injection grows fastest at 5.54% a year, as more patients with diabetes and other chronic conditions inject treatment at home.

How fast are safety designs replacing conventional devices?

Based on technology, the market is categorized into conventional devices, shielded safety devices and retractable safety devices. Conventional Devices led with a 58.0% share of 2025 value, because they cost less and remain standard for many uses outside hospitals. Retractable Safety Devices grow fastest at 6.68% a year, as health services adopt safety-engineered sharps to protect staff.

Diabetes care, safety buying and public health lift volumes

How does chronic disease treatment lift injection volumes?

Chronic disease treatment lifts injection volumes, because people with diabetes and other long-term conditions need regular injected medicines. Diabetes affected 7.4% of Australians aged 20 to 79 in 2024, according to the World Bank. People registered with the National Diabetes Services Scheme receive syringes and pen needles free, with up to 1,200 units every 180 days. People aged 65 and over also made up 18.1% of the population in 2025, which raises demand for injected therapies, blood tests and vaccines in clinics, pharmacies and homes. As a result, therapeutic injection holds 42.0% of 2025 value, while sales of human insulin and related injectables keep pharmacy demand steady.

Why does clinical safety procurement shape demand?

Clinical safety procurement shapes demand, because state purchasing agencies now list safety products alongside conventional devices. The Victorian hypodermic needles and syringes contract ran from Oct. 1, 2022, to Sept. 30, 2026, with one two-year option still available. It covers safety hypodermic needles, safety syringes, safety insulin syringes and safety insulin pen needles for public hospitals. NSW Health also issued a guideline on March 7, 2024, stating that safety-engineered sharps devices help cut sharps injuries. In turn, shielded and retractable safety devices gain share each year, because hospitals must trial new devices in the target area and review them within 12 months of introduction.

Download Free Sample

How does recurring public health demand support volumes?

Recurring public health demand supports volumes, because every vaccination season needs millions of needles and syringes. Australian providers recorded 8,960,904 influenza vaccination episodes from March 1 to Sept. 21, 2025, up 2.2% on 2024, according to the Department of Health. Western Australia recorded the largest rise, at 8.4%, while New South Wales recorded 2,683,712 episodes, the most of any state. The federal government also expanded the National Immunisation Program to include COVID-19 vaccines on Oct. 1, 2026, with adults aged 75 and over eligible for two doses a year. As a result, immunization holds a steady place, while programs such as pneumococcal vaccines add further injections each year.

Why do harm reduction programs add stable volumes?

Harm reduction programs add stable volumes, because state and territory health departments fund clean injecting equipment to prevent hepatitis C, HIV and other blood-borne infections. Australian programs distributed 64.4 million needles and syringes in 2024/25, according to the Kirby Institute. The national network had 4,612 outlets in 2025, including 3,134 pharmacy outlets and 458 syringe dispensing machines. Coverage reached 136% in 2024/25, or 889 needles and syringes per person who injects drugs each year. That coverage is more than four times the international high-coverage threshold. In turn, harm reduction gives suppliers large, regular public orders and states buy matching sharps containers for safe disposal.

Safety designs, pharmacies and vaccine changes shape use

How is the shift to safety-engineered sharps changing buying?

The shift to safety-engineered sharps is changing buying, because hospitals must reduce needlestick injuries among staff. NSW Health guideline GL2024_002, issued on March 7, 2024, says contaminated needle injuries are the main route of blood-borne virus exposure. It requires a sharps injury prevention program and a review of new safety devices within 12 months. The Victorian contract also lists at least 5 safety product types, from safety hypodermic needles and safety syringes to safety insulin syringes and safety pen needles. As a result, retractable safety devices grow fastest at 6.68% a year, while conventional devices keep 58.0% of 2025 value because they still cost less.

Why is the rise of pharmacy access notable?

The rise of pharmacy access is notable, because community pharmacies now supply both diabetes and harm reduction users. NDSS access points are usually community pharmacies, and out-of-stock products normally arrive within 24 to 48 hours. Pharmacies also made up 3,134 of the 4,612 needle and syringe program outlets across Australia in 2025, far more than any other outlet type. Registered NDSS users can also order up to a 6-month supply of syringes and pen needles before they travel overseas. In turn, ambulatory care and pharmacies grow faster than hospitals, and suppliers sell more boxed retail packs, insulin syringes, pen needles and diabetes care devices through pharmacy wholesalers.

Download Free Sample

Can the COVID-19 vaccine move to the national program open demand?

The COVID-19 vaccine move to the national program can open demand, because states now order and distribute these vaccines like other routine doses. The transition took effect on Oct. 1, 2026, replacing the standalone COVID-19 vaccine program. Adults aged 75 and over can receive 2 free doses a year, while adults aged 65 to 74 can receive 1 dose a year. Aboriginal and Torres Strait Islander people aged 50 to 74 also receive 1 dose a year. As a result, public health buyers can plan needle and syringe orders alongside influenza stock, which gives suppliers more predictable seasonal volumes across general practices, pharmacies and aged care homes.

Is there room to grow as public contracts are renewed?

Suppliers have room to grow as public contracts are renewed, because large state agreements set brands and prices for years. The principal period of the Victorian contract ended on Sept. 30, 2026, after four years, with one 2-year option left. The contract covers at least 16 product categories, from blunt and filter needles to catheter tip syringes. The Victorian supply agreement started on Oct. 1, 2022, and covered all Victorian public hospitals and health services. NSW Health also asks services to trial safety devices in the target area before wider use. In turn, suppliers with safety ranges, local stock and clinical trial support can win share, because public-sector buyers control most hospital volume in each state.

Tender pricing, waste rules and device costs test suppliers

How does tender pricing squeeze margins?

Tender pricing squeezes margins, because state purchasing agencies buy large volumes under multi-year contracts with fixed prices. As a result, suppliers of conventional syringes compete mostly on price and reliable delivery. Companies respond with safety ranges, bundled product lines and local warehousing, which help them win contracts on value rather than unit cost alone. Smaller suppliers often find it hard to meet the service terms of state contracts.

Why do safety device costs slow adoption?

Safety device costs slow adoption, because shielded and retractable designs cost more than conventional syringes and needles. In turn, clinics, aged care homes and community programs with tight budgets keep buying standard devices for many uses. Suppliers respond with injury cost data, staff training and trial stock, which help buyers compare the full cost of needlestick injuries against higher unit prices over a year of use.

How do sharps waste rules add cost?

Sharps waste rules add cost, because every used needle must go straight into a rigid, puncture-resistant container at the point of use. As a result, hospitals, pharmacies and needle programs pay for containers, collection and treatment of clinical waste. Suppliers respond with integrated safety devices and smaller packs, which reduce handling and help buyers meet state rules on safe disposal of used sharps in every care setting.

Why does import dependence create supply risk?

Import dependence creates supply risk, because most syringes and needles sold in Australia are made overseas and shipped through a few distributors. In turn, freight delays or factory problems can cause shortages during busy vaccination seasons. Buyers respond with buffer stock, multiple approved brands and longer supply contracts, which keep hospitals and programs supplied when shipments arrive late or demand rises suddenly.

NSW and ACT lead as Western and Central Australia rises

Why do New South Wales and the ACT hold the top share?

New South Wales and ACT held a 36.3% share of 2025 value and grow at 4.91% a year, because the zone has the largest population and hospital network. New South Wales recorded 2,683,712 influenza vaccination episodes from March to September 2025, the most of any state. The ACT recorded a further 205,914 episodes in the same period, up 5.8% on 2024. As a result, the zone leads hospital, pharmacy and vaccination demand, and Sydney hospitals buy the largest volumes of safety devices in the country.

How do Victoria and Tasmania support demand?

Victoria and Tasmania held a 26.3% share of 2025 value and grow at 5.11% a year, because Melbourne has a dense network of public and private hospitals. Victoria recorded 2,427,960 influenza vaccination episodes in the 2025 season, up 3.0%. Tasmania recorded a further 221,075 episodes in the same season, up 2.2%. Victorian public hospitals also buy needles and syringes through a single state contract, which concentrates volume with awarded suppliers and makes each renewal important for brand shares.

Download Free Sample

What shapes demand in Queensland?

Queensland held a 20.3% share of 2025 value and grows at 5.31% a year, because the state gains residents through interstate and overseas migration. Queensland added about 90,100 people in the year to March 2026. However, it was the only state where influenza vaccination episodes fell in 2025, by 1.1% to 1,732,463, which shows how seasonal demand can vary. Population growth in Brisbane and south-east Queensland still adds hospital and pharmacy volume each year.

Why is Western and Central Australia growing fastest?

Western and Central Australia held a 17.1% share of 2025 value and grows fastest at 5.61% a year, because Western Australia had the fastest population growth of any state, at 2.1%, in the year to March 2026. Western Australian influenza vaccination episodes also rose 8.4% in 2025. As a result, hospitals and pharmacies in Perth and Adelaide add steady volume.

Download Free Sample

Guidelines, vaccine data and contract milestones, 2024–2026

Shielded and retractable designs cut sharps injuries

• Conventional devices use a standard barrel, plunger and exposed needle, which keeps unit costs low and suits many routine uses in clinics and community programs.
• Shielded safety devices cover the needle with a hinged or sliding shield after use, which lowers the risk of needlestick injuries without changing the injection technique.
• Retractable safety devices pull the needle back into the barrel once the dose is given, which removes most exposure to the sharp and prevents reuse.

Global makers compete through tenders and distributors

Competition is led by global device makers that supply Australian hospitals, pharmacies and programs through local subsidiaries and medical distributors. Terumo syringes are sold to Australian healthcare businesses in sizes from 1 mL to 60 mL, with luer lock, luer slip, catheter and eccentric tip options. Braun Omnifix three-piece syringes are available through Australian laboratory and medical suppliers, while Nipro insulin syringes with fixed 27G and 29G needles are sold by Australian medical retailers. Rivals compete on safety features, needle comfort, reliable supply and price. Because state purchasing agencies decide which brands public hospitals buy, suppliers with full safety ranges and local stock win more contracts. Distributors also help brands reach pharmacies, aged care homes and general practices that order in smaller volumes.

Which companies supply Australian buyers?

Credence Research view on injection device demand

Credence Research's view is that Australian demand for syringes and needles will grow steadily because chronic disease care, vaccination and harm reduction create repeat use every year. General-purpose syringes remain the largest value pool, while safety designs add the fastest growth as hospitals act on needlestick injury guidance. Contract renewals in the larger states will decide which brands gain share. Suppliers with full safety ranges, reliable local stock and pharmacy reach should gain the most, while tender pricing keeps margins tight.

How the national injection device estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines vaccination statistics, needle and syringe program data, public procurement documents, health department guidelines, population statistics and supplier product listings. Segment splits and zone growth rates are Credence Research estimates, while zone shares follow the client-defined split. Sources used are official statistics, government publications, research institute program data and supplier listings, and no interviews or surveys were used.

Safety devices and home care carry growth to 2035

Device value is expected to reach USD 215.6 million by 2035, a 5.17% CAGR during 2026–2035, as Australians need more injected treatment, vaccination and harm reduction services. Growth should be strongest in safety devices, home care and pharmacy channels, because health services and patients move toward safer and more convenient products. Public contract renewals will shape brand shares in each state. Stronger safety rules would speed the shift away from conventional devices, while tight budgets could slow it.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.